Floatz logo

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE

Bevacizumab

Shanghai Minimally Invasive Surgery CenterSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Bevacizumab cohort.

Asset / SponsorPhaseRating
Iparomlimab
Nanfang Hospital, Southern Medical University
Phase 4BB
Calcium folinate pentahydrate
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2B
(+)-VINCRISTINE
Nanfang Hospital, Southern Medical University
Phase 2B
Befotertinib
Peng Zhang
Phase 2CCC

View all 10 →

Same molecule, other indications

5-FLUOROURACIL-1.BETA.-D-RIBOFURANOSIDE is also rated in:

Neoadjuvant TreatmentDormant
CCC
Indicative ·
48 / 100
View asset →
cancerDormant
CC
Indicative ·
46 / 100
View asset →
Rectal CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →